StockItOut
12 months ago
Yet beginning three days later Symetryx sold all its shares of NBSE.
It seems Symetryx and the Neubase Board were unable to find or see eye to eye on a suitable merger candidate. Or something else that promoted a large active investor to sell its entire position.
Symetryx exits stake in NeuBase Therapeutics, shares fall
Sep. 19, 2023 2:03 PM ET
NeuBase Therapeutics, Inc. (NBSE)
By: Deepa Sarvaiya, SA News Editor
NeuBase Therapeutics (NASDAQ:NBSE) falls 14% after disclosing that Symetryx has sold its entire position in the biopharmaceutical company.
Symetryx sold 203,337 shares in the price range of $1.19-$1.44. Symetryx has sold 680,081 shares in the last 10 days.
According to the form 4 [Sept. 14th, 2023], Symetryx now beneficially owns no shares in the company.
As per the recent filing on Sept. 06, Symetryx acquired 20% stake in NeuBase.
https://seekingalpha.com/filing/7872032?hasComeFromMpArticle=false
Is today's higher action a bounce, or a facilitated bounce, or something real?
.